Factors influencing the severity of COVID-19 course for patients with diabetes mellitus in tashkent: a retrospective cohort study
Anna V Alieva, Abdulaziz A Djalilov, Feruza A Khaydarova, Anvar V Alimov, Dilovar Z Khalilova, Vasila A Talenova, Nasiba U Alimova, Malika D Aripova, Akida S Sadikova
Obesity and metabolism, doi:10.14341/omet12801
Tashkent city health department, Uzbekistan BACKGROUND: Since the very first outbreak, scientists have been trying to determine the most critical pathogenetic mechanisms for the development of COVID-19 and related complications, analyze individual subpopulations of patients with chronic diseases and develop optimal tactics to combat not only the infection itself but also its acute and chronic complications. AIM: to assess the COVID-19 course among patients with Type 1 and Type 2 DM.
MATERIALS AND METHODS: A retrospective cohort study of Tashkent inhabitants, who had COVID-19 from April to December 2020, was performed. The data were obtained from the single electronic database of registered cases of COVID-19. All data were analyzed using a logistic regression in STATA 17.0 software. Further, the matched case-control study was performed for patients with type 2 DM and no DM based on age, gender, and BMI. RESULTS: Of the 5023 analyzed subjects, 72.63% had no diabetes mellitus (DM), 4.24% had type 1 DM, 15.19% had type 2 DM, and 7.94% was diagnosed with DM during the COVID-19 infection. DM, overweight, and obesity were associated with severe COVID-19; the most significant risk of a severe course was found in persons with type 2 DM. The risk of a lethal outcome and the need for prescription of glucocorticoids did not show a significant association with diabetes in Tashkent. The clinical features of COVID-19 were more common in patients with type 2 DM, especially for shortness of breath, chest pain, and arrhythmia. The persons receiving SU have complained of dyspnea significantly more often than matched patients without DM. Metformin and DPP4i were the groups of drugs that were not associated with significantly increased risk of hospitalization of patients because of COVID-19. The matched case-control study did not reveal statistically significant differences in the disease course severity, need for hospitalization and glucocorticoids, and death depending on the glucose-lowering therapy preceding the onset of COVID-19. CONCLUSION: Diabetes, age and overweight/obesity were associated with severe course of COVID-19 in Tashkent. There was no statistical difference in COVID-19 severity depending on initial glucose-lowering therapy.
ADDITIONAL INFORMATION Funding. This study was funded by the grant by the Ministry of Innovation of the Republic of Uzbekistan A-CC-2021-139.
Conflict of interest
References
Abu-Jamous, Anisimovich, Baxter, Associations of comorbidities and medications with COVID-19 outcome: a retrospective analysis of real-world evidence data. medRxiv,
doi:10.1101/2020.08.20.20174169Alieva, Djalilov, Khaydarova, Alimov, Khalilova et al., Factors influencing the severity of COVID-19 course for patients with diabetes mellitus in tashkent: a retrospective cohort study, Obesity and metabolism
Barron, Bakhai, Kar, Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a wholepopulation study, Lancet Diabetes Endocrinol,
doi:10.1016/S2213-8587(20)30272-2Bornstein, Rubino, Khunti, Practical recommendations for the management of diabetes in patients with COVID-19, Lancet Diabetes Endocrinol,
doi:10.1016/S2213-8587(20)30152-2Bramante, Ingraham, Murray, Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis, Lancet Heal Longev,
doi:10.1016/S2666-7568(20)30033-7Cariou, Hadjadj, Wargny, Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study, Diabetologia,
doi:10.1007/s00125-020-05180-xCasqueiro, Casqueiro, Alves, Infections in patients with diabetes mellitus: A review of pathogenesis, Indian J Endocrinol Metabol,
doi:10.4103/2230-8210.94253Chen, Yang, Cheng, Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication, Diabetes Care,
doi:10.2337/dc20-0660Cheng, Liu, Li, Metformin is associated with higher incidence of acidosis, but not mortality, in Individuals with COVID-19 and Pre-existing type 2 diabetes, Cell Metab,
doi:10.1016/j.cmet.2020.08.013Crouse, Grimes, Li, Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes, Front Endocrinol (Lausanne),
doi:10.3389/fendo.2020.600439Dalan, Ang, Tan, The association of Hypertension and Diabetes Pharmacotherapy with COVID-19 severity and immune signatures: an observational study, Eur Heart J Cardiovasc Pharmacother,
doi:10.1093/ehjcvp/pvaa098.pvaa098Fadini, Morieri, Longato, Exposure to dipeptidylpeptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: A case-control study, Diabetes, Obes Metab,
doi:10.1111/dom.14097Gao, Liu, Zhong, Risk of metformin in type 2 diabetes patients with COVID-19: a preliminary retrospective report, Clin Transl Sci,
doi:10.1111/cts.12897Grant, The effects of metformin on the fibrinolytic system in diabetic and non-diabetic subjects, Diabete metab
Guan, Liang, Zhao, Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis, Eur Respir J
Guo, Li, Dong, Diabetes is a risk factor for the progression and prognosis of COVID-19, Diabetes Metab Res Rev,
doi:10.1002/dmrr.3319Gupta, Ghosh, Singh, Misra, Clinical considerations for patients with diabetes in times of COVID-19 epidemic, Diabetes Metab Syndr,
doi:10.1016/j.dsx.2020.03.002Ho, Huang, Tsai, Metformin use mitigates the adverse prognostic effect of diabetes mellitus in chronic obstructive pulmonary disease, Respir Res,
doi:10.1186/s12931-019-1035-9Holman, Knighton, Kar, Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study, Lancet Diabetes Endocrinol,
doi:10.1016/S2213-8587(20)30271-0Izzi-Engbeaya, Distaso, Amin, Severe COVID-19 and diabetes e a retrospective cohort study from three London 2 teaching hospitals. medRxiv,
doi:10.1101/2020.08.07.20160275Jiang, Chen, Liu, Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: A retrospective cohort study, Diabetes Res Clin Pract,
doi:10.1016/j.diabres.2020.108619Kim, Jeon, Kim, The clinical characteristics and outcomes of patients with moderate-to-severe coronavirus disease 2019 infection and diabetes in Daegu, South Korea, Diabetes Metab J,
doi:10.4093/dmj.2020.0146Li, Wei, Li, Metformin use in diabetes prior to hospitalization: Effects on mortality in Covid-19, Endocr Pract,
doi:10.4158/EP-2020-0466Liang, Ding, Li, Association of preadmission metformin use and mortality in patients with sepsis and diabetes mellitus: a systematic review and meta-analysis of cohort studies, Crit Care,
doi:10.1186/s13054-019-2346-4Luo, Qiu, Liu, Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis, Am J Trop Med Hyg,
doi:10.4269/ajtmh.20-0375Mendy, Gopal, Alcorn, Forno, Reduced mortality from lower respiratory tract disease in adult diabetic patients treated with metformin, Respirology,
doi:10.1111/resp.13486Orcid, -mail: endocrin@uzsci.net Халилова Диловар Захириддиновна, Dilovar Z. Khalilova
Orcid, None
Orcid, alimovna@mail.ru Алимов Анвар Валиевич, д.м.н., профессор [Anvar V
Peleg, Weerarathna, Mccarthy, Davis, Common infections in diabetes: pathogenesis, management and relationship to glycaemic control, Diabetes Metab Res Rev,
doi:10.1002/dmrr.682Philipose, Smati, Wong, Obesity, old age, and frailty are the true risk factors for COVID-19 mortality and not chronic disease or ethnicity. medRxiv,
doi:10.1101/2020.08.12.20156257Raj, Mou, Smits, Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC, Nature,
doi:10.1038/nature12005Sinclair, Dhatariya, Burr, Guidelines for the management of diabetes in care homes during the Covid-19 pandemic, Diabet Med,
doi:10.1111/dme.14317Singh, Gupta, Ghosh, Misra, Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations, Diabetes Metab Synd,
doi:10.1016/j.dsx.2020.04.004Singh, Khunti, Assessment of risk, severity, mortality, glycemic control and antidiabetic agents in patients with diabetes and COVID-19: a narrative review, Diabetes Res Clin Pract,
doi:10.1016/j.diabres.2020.108266Singh, Singh, Saboo, Misra, Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A critical appraisal of literature, Diabetes Metab Syndr Clin Res Rev,
doi:10.1016/j.dsx.2020.12.026Tsoyi, Jang, Nizamutdinova, Metformin inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice, Br J Pharmacol,
doi:10.1111/j.1476-5381.2010.01126.xWargny, Potier, Gourdy, Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study, Diabetologia,
doi:10.1007/s00125-020-05351-wWu, Chen, Cai, Risk Factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease, JAMA Intern Med,
doi:10.1001/jamainternmed.2020.0994Xin, Wei, Ji, Metformin uniquely prevents thrombosis by inhibiting platelet activation and mtDNA release, Sci Rep,
doi:10.1038/srep36222You, Lee, Chun, Clinical outcomes of COVID-19 patients with type 2 diabetes: A populationbased study in Korea, Endocrinol Metab,
doi:10.3803/EnM.2020.787Yuan, Qi, Peng, Molecular basis of binding between Middle East Respiratory Syndrome Coronavirus and CD26 from seven bat species, J Virol,
doi:10.1128/JVI.01387-19Zhang, He, Impacts of metformin on tuberculosis incidence and clinical outcomes in patients with diabetes: a systematic review and meta-analysis, Eur J Clin Pharmacol,
doi:10.1007/s00228-019-02786-yАлиева, Валерьевна, Anna, Alieva, Md, адрес: Республика Узбекистан, 100125, Ташкент, ул. Мирзо Улугбека, д. 56 [address: 56, M. Ulugbek str
Информация Об Авторах, None
Малика Дильшадовна, Md [malika, Aripova, Orcid, None
Насиба, None, PhD [Nasiba U. Alimova, PhD
